氟伐他汀和血脂康治疗肾移植术后高脂血症的疗效和安全性研究

目的:考察氟伐他汀和血脂康治疗肾移植术后高脂血症的疗效和安全性。方法:56例肾移植术后高脂血症患者分为氟伐他汀组(n=32,氟伐他汀40～80mg,口服,每日1次,疗程8周)和血脂康组(n=24,血脂康0.6g,口服,每日2次,疗程8周)。观察2组治疗前、后总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)及肝、肾功能的变化。结果:氟伐他汀组治疗后,TC由(7.39±1.98)mmol·L-1降至(5.62±0.93)mmol·L-1,LDL由(3.68±1.13)mmol·L-1降至(2.86±0.83)mmol·L-1;血脂康组治疗后,TC由(6.82±1.29)mmol·L-1降至(5.56±1.19)mmol·L-1,LDL由(3.26±0.73)mmol·L-1降至(2.78±0.80)mmol·L-1;与治疗前相比均有显著性差异(P<0.01或P<0.05)。2组间TC和LDL降幅无显著性差异,且TG水平在治疗前、后无明显变化(P>0.05)。治疗过程中2组均未发生明显不良反应。结论:氟伐他汀和血脂康治疗肾移植术后高脂血症安全、有效。

Efficacy and Safety of Fluvastatin vs. Xuezhikang for Hyperlipidemia after Renal Transplantation

OBJECTIVE： To evaluate the efficacy and safety of Fluvastatin vs. Xuezhikang for hyperlipidemia in patients after renal transplantation. METHODS： 56 hyperlipidemia patients after renal transplantation were enrolled： 32 were assigned to receive Fluvastatin （40--80 mg） po qd for 8 weeks and 24 to receive Xuezhikang （0.6 g） po bid for 8 weeks. Total cholesterol （TC）, triglyceride （TG）, low-density lipoprotein-cholesterol （LDL）, high-density lipoprotein-cholesterol （HDL）, liver function and renal function in two groups were measured before and after treatment.RESULTS： In Fluvastatin-treated group, the TC decreased from（7.39± 1.98） mmol·L^-1 to（5.62±0.93） mmol·L^-1, LDL reduced from（3.68± 1.13）mmol·L^-1 to （2.86± 0.83）mmol·L^-1; in Xuezhikang-treated group, TC decreased from（6.82± 1.29）mmol·L^-1 to （5.56± 1.19）mmol·L^-1 and LDL decreased from （3.26± 0. 73） mmol·L^-1 to （2.78 ± 0.80） mmol·L^-1, all showing significant differences as compared with before treatment（P〈0.01 or P 〈 0.05）. There were no significant differences between the two groups in the reductions of TC and LDL, nor was there significant change in TG level before and after treatment in either group （P 〉 0.05） .No obvious adverse effect was noted in either group during treatment. CONCLUSION ： Both Fluvastatin and Xuezhikang are safe and effective for hyperlipidemia in patients after renal transplantation.